Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload

Selective SGLT2 inhibition reduces the risk of worsening heart failure and cardiovascular death in patients with existing heart failure, irrespective of diabetic status. We aimed to investigate the effects of dual SGLT1/2 inhibition, using sotagliflozin, on cardiac outcomes in normal diet (ND) and h...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, Sophia L., Ryan, Lydia, Mullins, Thomas P., Flint, Melanie, Steane, Sarah E., Walton, Sarah L., Bielefeldt-Ohmann, Helle, Carter, David A., Reichelt, Melissa E., Gallo, Linda A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490778/
https://www.ncbi.nlm.nih.gov/pubmed/34621187
http://dx.doi.org/10.3389/fphys.2021.738594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490778/
https://www.ncbi.nlm.nih.gov/pubmed/34621187
http://dx.doi.org/10.3389/fphys.2021.738594

Ejemplares similares